Filter by year
June 25, 2024
Market Authorisation Application (MAA) for UM171 Cell Therapy accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for adult patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor MONTREAL, June 25, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell expansion and […]
Read moreJune 4, 2024
– UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) – The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy (INN-dorocubicel) an additional orphan drug designation to enhance cell engraftment and immune reconstitution MONTREAL, June 4, […]
Read moreMarch 27, 2024
– Dr. Guy Sauvageau, Chief Scientific Officer at ExCellThera will present on current indications and prospects of hematopoietic stem cell expansion at the EBMT 2024 Annual Meeting. MONTREAL, March 27, 2024 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today that Dr. Guy Sauvageau, the company’s Chief […]
Read moreFebruary 1, 2024
– Data expand on previously described mechanism of action and validate use of UM171 to create improved hematopoietic stem cell (HSC) therapies, including UM171 Cell Therapy – Company expects to initiate a Phase 3 study for UM171 Cell Therapy for the treatment of high and very high-risk acute leukemias and myelodysplasias in 2024 MONTREAL, February […]
Read moreJanuary 2, 2024
MONTREAL, January 2, 2024 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today that its senior leaders will be holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA, and will be participating in the following investor conferences in January: 2024 Biotech […]
Read more